In a report published in The Lancet Infectious Diseases (Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials) a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable protective efficacy against malaria shown by Sanaria® PfSPZ Vaccine when administered to women prior to pregnancy.
AI model predicts future spread of SARS-CoV-2 variants using genomic data
Researchers developed an AI-based model to predict the spread of new SARS-CoV-2 variants, analyzing nine million genomic sequences across 30 countries and incorporating factors like